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Introduction: Despite increased use of vaccine in routine immunisation, rotavirus remains a major cause
of acute gastroenteritis (AGE) in low-income countries. We describe rotavirus prevalence and hospitali-
sation in Malawi pre and four years post vaccine introduction; provide updated vaccine effectiveness (VE)
estimates; and assess rotavirus vaccine indirect effects.
Methods: Children under five years of age presenting to a referral hospital in Blantyre with AGE were
recruited. Stool samples were tested for rotavirus using Enzyme Immunoassay. The change in rotavirus
prevalence was evaluated using Poisson regression. Time series analysis was used to further investigate
trends in prevalence over time. VE against rotavirus diarrhoea of any severity was estimated using
logistic regression. Indirect effects were estimated by evaluating rotavirus prevalence in unvaccinated
children over time, and by comparing observed reductions in incidence of rotavirus hospitalisation to
those expected based on vaccine coverage and trial efficacy estimates.
Results: 2320 children were included. Prevalence of rotavirus in hospitalised infants (<12 months) with
AGE decreased from 69/139(49.64%) prior to vaccine introduction to 197/607(32.45%) post-vaccine
introduction (adjusted RR 0.67[95% CI 0.55, 0.82]). Prevalence in children aged 12–23 months demon-
strated a less substantial decline: 15/37(40.54%) pre- and 122/352(34.66%) post-vaccine introduction
(adjusted RR 0.85, 95% CI 0.57, 1.28). Adjusted VE was 61.89%(95% CI 28.04–79.82), but lower in children
aged 12–23 months (31.69% [95% CI 139.03 to 80.48]). In hospitalised infants with rotavirus disease, the
observed overall effect of the vaccine was 9% greater than expected according to vaccine coverage and
efficacy estimates. Rotavirus prevalence among unvaccinated infants declined post-vaccine introduction
(RR 0.70[95% CI 0.55–0.80]).
Conclusions: Following rotavirus vaccine introduction in Malawi, prevalence of rotavirus in hospitalised
children with AGE has declined significantly, with some evidence of an indirect effect in infants. Despite
this, rotavirus remains an important cause of severe diarrhoea in Malawian children, particularly in the
second year of life.
 2018 Published by Elsevier Ltd.1. Introduction
Prior to widespread routine vaccination, rotavirus was the com-
monest cause of childhood diarrhoea worldwide and in 2008 wasMalawi
2 A. Bennett et al. / Vaccine xxx (2018) xxx–xxxestimated to be responsible for over 450,000 annual deaths [1].
Following World Health Organization (WHO) recommendation in
2009 [2], rotavirus vaccine has been introduced in 81 countries,
including 37 low- and middle-income countries (LMICs) eligible
for support from Gavi: the Vaccine Alliance [3]. In pre-licensure
trials, substantially lower vaccine efficacy was observed in LMICs
(39–72%) compared with high-income countries (98–100%)
[4–9]; however, post-introduction vaccine effectiveness estimates
from LMICs have been encouraging (60–70%) [10–13]. In the con-
text of continued global roll-out of rotavirus vaccine, it is impor-
tant to describe persistence of population impact and to quantify
the residual burden of rotavirus disease, particularly amongst
young children hospitalised with gastroenteritis.
Despite high levels of vaccine uptake (90–98%), in several LMICs
over 20% of hospitalised gastroenteritis remains attributable to
rotavirus [11,13,10]. In high-income settings, vaccine effectiveness
(VE) appears to be sustained in the second year of life [14], but
reports of persistence of protection in LMICs are mixed [15]. Some
LMICs, including Malawi, have reported lower effectiveness esti-
mates in the second year of life [11,16], while others have observed
sustained protection [15,17]. In addition to the direct effects of
vaccination, the indirect effects of rotavirus vaccine may con-
tribute substantially to the overall population impact, particularly
in countries where VE is suboptimal. Evidence of indirect effects
from well-resourced settings exists [18], but data describing indi-
rect effects from LMICs are lacking [13]. Because of differences in
factors such as population density and patterns of contact that
could affect the force of infection, the indirect effects of vaccination
in LMICs could differ from well-resourced settings [19].
Malawi introduced monovalent rotavirus vaccine (RV1) on 29
October 2012, with doses at 6 and 10 weeks of life. We have previ-
ously published VE estimates and population impact 3 years after
vaccine introduction [11,12]. In this prospective observational
study, we aimed to describe the prevalence of rotavirus hospitali-
sation in urban Blantyre, Malawi, 4 years after vaccine introduc-
tion, update published vaccine effectiveness estimates, and
investigate for evidence of rotavirus vaccine indirect effects.2. Methods
This study was conducted at Queen Elizabeth Central Hospital
(QECH), Blantyre, Malawi. QECH is the only government hospital
providing free inpatient care to the estimated 151,328 under-5
population of Blantyre City [11]. Active surveillance for acute
gastroenteritis has been conducted at QECH since 1997; this paper
describes the period of enhanced surveillance commencing 1
January 2012 to 30 June 2016.
Our surveillance platform has been described previously in
detail [11,12]. Briefly, children presenting to QECH with acute gas-
troenteritis (AGE) during routine clinical hours are enrolled follow-
ing informed consent. Detailed demographic and clinical data are
recorded, anthropometric assessment undertaken and bulk stool
sample collected. HIV testing is conducted according to national
guidance [20]. Vaccine status is obtained from government-
issued family-held records. Disease severity is defined using Vesi-
kari score [21]; a score of 11/20 indicates severe disease. HIV
infection is defined based on a positive rapid test (12 months of
age), or positive HIV DNA PCR (<12 months). HIV exposure is
defined as a positive maternal HIV rapid test. Nutritional status
is assessed using WHO standards, where severe acute malnutrition
(SAM) is defined as anyone of weight-for-height Z-score (WHZ)<-3
SD from WHO standard, mid-upper-arm circumference (MUAC)
<115 mm, or nutritional oedema [22]. Within the surveillance plat-
form, a nested case-control study identified children with AGE who
were age-eligible for vaccination and produced a stool sample thatPlease cite this article in press as: Bennett A et al. Direct and possible indirect ef
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cases, and rotavirus test-negative controls.
2.1. Laboratory methods
Stool samples were batch-tested weekly for rotavirus antigen
using enzyme immunoassay (EIA, Rotaclone, Meridian Bioscience,
Cincinnati, Ohio). HIV testing of mothers and children was con-
ducted using two sequential EIA rapid tests (Determine HIV-1/2
[Abbott Laboratories, USA] and Uni-Gold HIV [Trinity Biotech
PLC, Ireland]), or HIV DNA PCR for infants under one year of age
[20].
2.2. Statistical analysis
2.2.1. Descriptive analysis
Continuous normally distributed data were described using
mean and standard deviation (SD), or median and interquartile
range otherwise. Differences in independent categorical covariates
were assessed using v2 tests. Student’s t or rank sum tests were
used to compare independent means or medians, respectively.
2.2.2. Prevalence changes over time of EIA-positive rotavirus
To evaluate yearly differences in rotavirus prevalence since vac-
cine introduction, we analysed the surveillance platform as a
cohort and used Poisson regression models with robust standard
errors [23] to estimate the relative risk of rotavirus in hospitalised
AGE cases compared to the year preceding introduction. Models
were adjusted for age and month of presentation, and analysis
restricted to the first 6 months (January to June) of each year for
consistency.
2.2.3. Time series analysis
We used time series analysis to describe trend and seasonality
in the prevalence of rotavirus in diarrhoeal stools over time. We
applied a locally weighted smoother (defined as (1/8) ⁄ [1 ⁄ x(t 
2) + 2 ⁄ x(t  1) + 2 ⁄ x(t) + 2 ⁄ x(t + 1) + 1 ⁄ x(t + 2)]) to mean
monthly proportion of rotavirus-positive stools to define seasonal-
ity and a second locally weighted smoother (defined as (1/24) ⁄
[1 ⁄ x(t  6) + 2 ⁄ x(t-5) + 2 ⁄ x(t  4) + 2 ⁄ x(t  3) + 2 ⁄ x(t  2)
+ 2 ⁄ x(t  1) + 2 ⁄ x(t) + 2 ⁄ x(t + 1) + 2 ⁄ x(t + 2) + 2 ⁄ x(t + 3) +
2 ⁄ x(t + 4) + 2 ⁄ x(t + 5) + 1 ⁄ x(t + 6)], where x(t) = percentage
rotavirus-positive stools per month) to the same to define secular
trend. Trend in rotavirus prevalence over time was then assessed in
a linear model.
2.2.4. Case-control analysis for vaccine effectiveness
Vaccine effectiveness (VE) was estimated from the nested case-
control study as (1-Odds Ratio for 2 vs 0-dose vaccine receipt)
among rotavirus EIA-positive rotavirus cases against EIA test-
negative gastroenteritis controls, defined as described above, using
unconditional logistic regression, and reported as a percentage.
Estimates were adjusted for age and for secular and seasonal fluc-
tuations using indicator variables for year and month of admission.
2.2.5. Estimating indirect vaccine effects
Poisson regression models with robust standard errors were
used to identify any change in the prevalence of rotavirus-
positive gastroenteritis among unvaccinated admitted infants
(<12 months of age) and children (12–59 months of age) following
introduction of rotavirus vaccine using all available data. We then
estimated the expected overall reduction in incidence of rotavirus
gastroenteritis among admitted infants based on the direct effect
of vaccination alone and compared this to the observed overall
reduction. We made the assumption that any additional observed
reduction in incidence may be attributed to the indirect effects offects of vaccination on rotavirus hospitalisations among children in Malawi
.1016/j.vaccine.2018.04.030
Table 1
Demographic data.
Characteristic Denominator
Male (n, %) 1339 (57.77) 2318
Age in months (median, IQR) 10.68 (7.72, 15.29) 2320
Weight for height Z score (WHZ)*
(mean, SD)
0.85 (1.89) 2292
Severe acute malnutrition (n, %)* 396 (17.31) 2288
RV coverage** (n, %)
0 doses 43 (3.81) 1130
1 dose 60 (5.31) 1130
2 doses 1027 (90.88) 1130
HIVϮ
Infected (n, %) 71 (4.03) 1761
Exposed (n, %) 426 (18.80) 2266
* Weight corrected by adding 10% to weights for those with severe disease to
account for dehydration.
** In those vaccine age-eligible with health record confirmation.
Ϯ HIV infected is defined as a positive HIV rapid test over 12 months of age, or a
positive HIV DNA PCR result. HIV exposed is defined as a positive maternal HIV
rapid test.
A. Bennett et al. / Vaccine xxx (2018) xxx–xxx 3the vaccine [24]. Because we did not have data for a full calendar
year prior to rotavirus vaccine introduction, incidence estimates
were calculated for the first 6 months of each year. This was done
using the following method [24]:
i. Incidence (case numbers per 100,000 age-specific popula-
tion per 6 months) was estimated using projected popula-
tion estimates for Blantyre city, based on the proportion of
infants at the national level.
ii. The expected population direct effect (assuming any reduc-
tion in the overall incidence was due only to the direct effect
of vaccination) was calculated as vaccine coverage  vaccine
efficacy,
where both vaccine coverage and efficacy were expressed as
proportions and using a value of vaccine efficacy of 49.4% for
severe disease in infants, 34.5% for all rotavirus gastroenteri-
tis in infants and 17.6% for children with severe disease [6,7].
No efficacy estimates were available for disease of all sever-
ity in children, so expected effects were not calculated for
this group.
iii. The observed overall effect was calculated by comparing the
semi-annual post-vaccination incidence to incidence for the
half-year prior to vaccine introduction (January to June
2012) using:
(pre-vaccine incidence – post-vaccine incidence)/pre-
vaccine incidence.
iv. The estimated indirect effect was calculated as observed
effect – expected effect [24].
For comparison purposes and to look for evidence of secular
trends in diarrhoeal admissions to QECH, the incidence rate of hos-
pitalised rotavirus-negative gastroenteritis was estimated using
the denominators described above to estimate child-years at risk,
and change over time was evaluated using incidence rate ratios.
Analyses were restricted to those children with stool samples
collected. All analyses except VE estimates were restricted to
admitted children. For analysis of trend in rotavirus prevalence
and VE estimates, children were categorised into <12 month or
12–23 month age groups. For assessment of vaccine indirect
effects, children up to 59 months of age were included. Analyses
were conducted using Stata 12.1 (TMStatacorp, College Station,
Texas USA).
2.3. Ethics
Ethical approval was obtained from the National Health
Sciences Research Committee, Lilongwe, Malawi (867), and by
the University of Liverpool Research Ethics Committee (000490).3. Results
Stool samples were collected from a total of 2320 children
(median age 10.68 months, interquartile range [IQR] 7.72, 15.29)
between 1st January 2012 and 30 June 2016. Of these, 1318
(median age 10.04 months, IQR 7.59–13.63) were eligible for both
doses of rotavirus vaccine, and 1130 (median age 9.74 months, IQR
7.43–12.75) had documented evidence of vaccine status.
Characteristics of the population are shown in Table 1.
3.1. Overall decline in rotavirus prevalence
In the four years since vaccine introduction, the relative risk of
rotavirus among children admitted with diarrhoeal disease has
consistently declined (Table 2 and Fig. 1); however, over 25% of
all gastroenteritis admissions remain rotavirus positive (Table 2).Please cite this article in press as: Bennett A et al. Direct and possible indirect ef
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13.54) months prior to vaccine introduction to 10.86 (IQR 7.95,
15.41) months following vaccine introduction (rank sum test p <
0.001). The adjusted relative risk of rotavirus positivity among
infants hospitalised with gastroenteritis in the first 6 months of
the year has decreased from 69/139 [49.64%] to 197/607 [32.45%]
since vaccine introduction (adjusted RR 0.67 [95% CI 0.55, 0.82]
p < 0.001). This effect is smaller in children aged 12–23 months,
where the relative risk pre- and post-introduction respectively
was 15/37 (40.54%) and 122/352 (34.66%) (adjusted RR 0.85 [95%
CI 0.57, 1.28] p = 0.440) (Fig. 1). The proportion of admitted
rotavirus-positive cases aged 12–23 months increased from
15/84 (17.86%) in the January to June prior to vaccine introduction
to 122/319 (38.24%) subsequent to vaccine introduction
(v2p<0.001). Linear regression showed a significant negative trend
in prevalence of rotavirus over time in infants (regression coeffi-
cient 0.35 [95% CI 0.46, 0.25] P < 0.001) and in children aged
12–23 months (regression coefficient 0.43 [95% CI 0.51,
0.36] p < 0.001), where the regression coefficient represents the
percentage change in rotavirus positivity per month.
3.2. Vaccine effectiveness estimates
The adjusted VE for two doses of vaccine, across all ages and
disease severity was 61.89% (95% CI 28.04%, 79.82%) (Table 3),
whilst VE against all disease in the 12–23 month age group was
31.69% (95% CI 139.03%, 80.48%). VE against severe disease
among children <12 months of age was 83.24% (95% CI 53.81%,
93.92%).
3.3. Indirect vaccine effects
Among unvaccinated infants with gastroenteritis, rotavirus
prevalence declined from 117/221 (52.94%) in the 10 months prior
to vaccine introduction to 65/184 (35.33%) in the 14 months fol-
lowing vaccine introduction (adjusted RR 0.70 [95% CI 0.55, 0.88]
p = 0.003) (Fig. 2). This analysis was truncated at 24 months from
the start of surveillance because the vast majority of infants after
this time-point were vaccinated. Comparing the observed against
expected reduction in incidence showed a difference of between
9 and 24% in admitted infants with rotavirus gastroenteritis of
any severity (Table 4). Restricting to infants with severe rotavirus
gastroenteritis, no difference was seen (Table 4). In unvaccinated
children 12–59 months of age there was no evidence of a declinefects of vaccination on rotavirus hospitalisations among children in Malawi
.1016/j.vaccine.2018.04.030
Table 2
Relative risk of rotavirus detection in children admitted to QECH with gastroenteritis.
RV** negative RV positive Total RR (95% CIϮ)*
Time period
Pre-vaccine (Jan’12-Jun’12) 110 (56.70) 84 (43.30) 194 1 (REF)
Jan’13-Jun’13 185 (58.18) 133 (41.82) 318 0.95 (0.78–1.16)
Jan’14-Jun’14 177 (69.96) 76 (30.04) 253 0.77 (0.61–0.98)
Jan’15-Jun’15 219 (75.26) 72 (24.74) 291 0.60 (0.46–0.77)
Jan’16-Jun’16 132 (72.13) 51 (27.87) 183 0.74 (0.57–0.98)
Total 823 (66.42) 416 (33.58) 1239
* Adjusted for age in months and month at admission. Relative risk for rotavirus gastroenteritis vs test-negative gastroenteritis.
Ϯ 95% confidence interval.
** Rotavirus (RV).
Fig. 1. Monthly diarrhoeal admissions to QECH.
Table 3
Vaccine effectiveness estimates.
N (Rotavirus positive, vaccinated [%])** N (Rotavirus positive unvaccinated [%])** Vaccine effectiveness (95% CI) P value
Adjusted*
2 doses 275/1019 (26.99) 20/43 (46.51) 61.89 (28.04–79.82) 0.003
Disease severity* (all ages)
Severe 243/788 (30.84) 15/25 (60.00) 74.75 (41.49–89.10) 0.001
Mild/mod 30/214 (14.02) 4/17 (23.53) 25.81 (165.58–79.27) 0.646
By age* (all severity)
<12 m 190/696 (27.30) 16/29 (55.17) 74.88 (44.59–88.61) 0.001
12–23 m 78/285 (27.37) 4/13 (30.77) 31.69 (139.03–80.48) 0.551
By age* (severe disease)
<12 m 166/547 (30.35) 13/19 (68.42) 83.24 (53.81–93.92) 0.001
12–23 71/215 (33.02) 2/6 (33.33) 7.58 (444.91–84.33) 0.931
* Adjusted for age, and year and month of presentation. All are two-dose estimates.
** Where N refers to the number of rotavirus positive cases; denominator is all gastroenteritis cases with stool sample collected, vaccinated indicates 2 doses of monovalent
rotavirus vaccine received and unvaccinated indicates 0 doses.
4 A. Bennett et al. / Vaccine xxx (2018) xxx–xxxin the prevalence of rotavirus following vaccine introduction, with
26/84 (30.95%) rotavirus positive pre-vaccine introduction and
70/193 (36.27%) rotavirus positive after introduction, RR 1.14
(95% CI 0.79, 1.63). This analysis was restricted to 36 months after
the start of surveillance. There was also no evidence of an indirectPlease cite this article in press as: Bennett A et al. Direct and possible indirect ef
four years after programmatic introduction. Vaccine (2018), https://doi.org/10effect demonstrated on comparison of observed vs expected reduc-
tions in incidence (Table 4).
In contrast to the incidence rate of rotavirus-positive hospitali-
sations, the incidence of hospitalisation for rotavirus-negative
gastroenteritis increased over time. The incidence rate offects of vaccination on rotavirus hospitalisations among children in Malawi
.1016/j.vaccine.2018.04.030
Fig. 2. Monthly diarrhoeal admissions to QECH in unvaccinated infants – note data truncated at 24 months from start of surveillance (14 months from vaccine introduction)
due high vaccine coverage.
Table 4
Comparison of expected and observed vaccine effects by year since vaccine introduction.
Incidence* RV coverage** (%) Expected effect (%) Observed effect (%) Difference in observed effect (%)
<12 m severe RV GE
Jan’12-Jun’12Ϯ 183 – – – –
Jan’13-Jun’13 210 29.60 14.62 14.83 29.45
Jan’14-Jun’14 110 92.93 45.91 39.75 06.15
Jan’15-Jun’15 116 94.16 46.52 36.22 0.10
Jan’16-Jun’16 99 94.29 46.58 45.92 0.66
All post vaccine 134 76.61 37.85 26.76 11.08
<12 m all RV GE
Jan’12-Jun’12 Ϯ 234 – – – –
Jan’13-Jun’13 256 29.41 10.21 9.22 19.43
Jan’14-Jun’14 139 90.08 31.26 40.73 9.47
Jan’15-Jun’15 123 94.32 32.73 47.45 14.73
Jan’16-Jun’16 102 92.31 32.03 56.39 24.13
All post vaccine 155 73.16 25.39 33.84 8.45
12–60 m severe RV GE
Jan’12-Jun’12 Ϯ 14 – – – –
Jan’13-Jun’13 Ϯ Ϯ 58 – – – –
Jan’14-Jun’14 26 64.00 11.26 79.71 90.98
Jan’15-Jun’15 26 90.77 15.98 81.28 97.26
Jan’16-Jun’16 14 95.12 16.74 0.30 17.04
All post vaccine 22 85.17 14.96 53.76 68.73
* 6 month Jan to June, per 100,000 children.
** % coverage for 2nd dose of rotavirus vaccine.
Ϯ Prior to vaccine introduction.
Ϯ Ϯ Period from Jan’13 to Jun’13 excluded for children over 12 months as these children were not vaccine age eligible.
A. Bennett et al. / Vaccine xxx (2018) xxx–xxx 5hospitalisation with rotavirus-negative gastroenteritis among
infants was 479 per 100,000 child-years at risk prior to rotavirus
vaccine introduction and 655 per 100,000 child-years at risk subse-
quently (incidence rate ratio 1.37 [95% CI 1.06, 1.79]). For children,
the incidence rate for hospitalisation with rotavirus-negative gas-
troenteritis was 77 per 100,000 child-years pre- and 136 per
100,000 child-years post-rotavirus-vaccine introduction (incidence
rate ratio 1.77 [95% CI 1.27, 2.52]).4. Discussion
Four years after programmatic rotavirus vaccine implementa-
tion in Malawi, we continue to demonstrate VE against rotavirus
disease of all severity (VE 61.89%, 95% CI 28.04–79.82%), and a con-
sistent decline in the prevalence of rotavirus in children presenting
to hospital with gastroenteritis. There is some evidence of a reduc-
tion in disease among unvaccinated infants, possibly attributable
to indirect vaccine effects. However, children aged 12–23 months
demonstrate a less pronounced reduction in disease and a lowerPlease cite this article in press as: Bennett A et al. Direct and possible indirect ef
four years after programmatic introduction. Vaccine (2018), https://doi.org/10point estimate for VE compared to those under 12 months of age,
and overall there remains a significant residual burden of disease
with rotavirus associated with just over 1 in 4 gastroenteritis
admissions.
Gavi support has allowed LMICs such as Malawi to successfully
introduce rotavirus vaccination. However, in the long-term immu-
nisation programmes must be locally funded. Robust vaccine effec-
tiveness estimates, demonstration of sustained impact, and
evaluation of indirect effects are essential to allow national govern-
ments to evaluate the cost-effectiveness of vaccines. A major
strength of our study is its basis in a long-standing surveillance
system, within which a case-control study to evaluate vaccine
effectiveness has been nested. As vaccine coverage increases, and
as it becomes increasingly difficult to identify unvaccinated chil-
dren for the case-control study, on-going surveillance will allow
evaluation of incidence over time. The high vaccine effectiveness
seen in infants with severe disease (83.24% [95% CI 53.81%,
93.92%] is striking. Although this result should be interpreted
within the context of moderately wide confidence limits, it is con-
sistent with our previously reported estimates for Malawi and withfects of vaccination on rotavirus hospitalisations among children in Malawi
.1016/j.vaccine.2018.04.030
6 A. Bennett et al. / Vaccine xxx (2018) xxx–xxxrecent estimates for RV5 from Rwanda [25], and together with the
demonstration of robust vaccine effectiveness against rotavirus
disease of any severity is encouraging evidence of real-world value
of rotavirus vaccines in preventing disease in low-income
countries.
Effectiveness point estimates in children aged 12–23 months
appear lower than those in infants. The confidence bounds around
these estimates are wide, and it is possible that this simply reflects
uncertainty in point estimates as a result of fewer AGE episodes in
the older age group, but the finding is corroborated by the relative
risk of rotavirus gastroenteritis compared to test-negative controls,
which has not decreased in this age group, and the proportion of
rotavirus cases occurring in children 12–23 months of age, which
has increased from 18% to 38% following vaccine introduction. This
lower VE in the second year of life is consistent with observations
in Colombia and Brazil [26,27], but inconsistent with South Africa
and Botswana [15,17]. While it is possible that the lower VE is due
to immunological waning (indeed a randomised controlled trial
(RCT) in Malawi showed a non-significantly higher vaccine efficacy
in the second year of life among infants given a three-dose RV1
schedule [7,28]), our findings could also be explained by an epi-
demiological phenomenon. A high force of rotavirus infection in
countries like Malawi results in unvaccinated children experienc-
ing frequent wild-type rotavirus exposure over time, providing
natural immunity even among the unvaccinated. This effect could
then lead to a reduction in observed VE in the second year of life as
time for wild-type exposure to occur has accumulated.
Indirect effects of rotavirus vaccine have been observed in high-
income countries [18], but there is currently little evidence from
LMICs [13]. We observed reductions in the relative risk of
rotavirus-positive gastroenteritis in unvaccinated infants in the
year following vaccine introduction, though the reliability of this
estimate is limited by the short duration of observation. Available
data across all months were included for this analysis to maximise
data availability, acknowledging the possibility that this could
introduce some seasonal bias. Sensitivity analysis restricting to
the first 6 months of the year resulted in similar observations to
the full period analysis, but the results were no longer significant.
Comparison of observed with expected overall reductions in rota-
virus incidence showed greater reductions than would be
explained by direct effects alone in infants with disease of any
severity. However, this effect was not observed among infants with
severe disease or among children 12–59 months of age.
The absence of observed indirect effects in these groups is con-
trary to findings from higher income settings and from Rwanda
[13,18], but supported by studies from Zambia and South Africa
which found no evidence of a rotavirus vaccine indirect effect in
children too old to receive vaccine [29,30]. The absence of identifi-
able indirect effects in infants with severe disease could potentially
be explained by the larger vaccine efficacy estimate in this group.
One explanation for the absence of identifiable indirect effect in
children over 12 months of age could be that prior to vaccine intro-
duction, older children in Malawi experienced a low frequency of
clinical disease because of frequent natural exposure to rotavirus
and consequent natural immunity. A reduction in transmission in
the time-period immediately following vaccine introduction may
therefore confer no additional protection.
These findings could however also represent under-
ascertainment by this study. In particular, our measurement of
indirect effects only captures the effect on hospitalised cases which
are a small proportion of the community burden of rotavirus dis-
ease, and the observed increase in incidence of hospitalisation with
rotavirus-negative diarrhoeal disease following vaccine introduc-
tion could bias estimation of vaccine impact based on hospitalised
cases and estimation of indirect effects derived from this towards
the null. Increasingly high vaccine coverage limits further analysisPlease cite this article in press as: Bennett A et al. Direct and possible indirect ef
four years after programmatic introduction. Vaccine (2018), https://doi.org/10of indirect effects, and mathematical modelling may be required to
investigate the presence and extent of such effects in greater
depth.
It is not clear why we observed an increase in incidence of test-
negative diarrhoeal cases following vaccine introduction. This
could represent secular changes in health-care seeking behaviour
or admission patterns with time, but also may reflect the short
period of enhanced surveillance before this point, which limits
assessment of trends in rotavirus prevalence prior to vaccine intro-
duction. Prevalence estimates can be affected by secular changes in
denominators, and ongoing surveillance is required to evaluate the
long term impact of vaccine in our setting.5. Conclusions
Our data demonstrate substantial and consistent reductions in
rotavirus prevalence in hospitalised children four years since vac-
cine introduction and robust vaccine effectiveness against all-
severity rotavirus disease in infants reinforcing the importance of
rotavirus vaccine in reducing the burden of disease in low-
income countries. Additionally our data suggest the presence of
population indirect effect in infants, although not in other age
groups. Although factors other than vaccine introduction may also
contribute to overall disease reduction, our analysis was not
designed to formally account for these. We are however, unaware
of major health system or socioeconomic or nutritional changes in
Malawi over the period of our observation that might have also
contributed to reductions in disease incidence. Importantly, our
data also show the persistent burden of rotavirus, particularly in
children in the second year of life. Given the ongoing prevalence
of rotavirus disease in this population, strategies to further
improve the effectiveness of current vaccines maybe required to
maximise protection for all children against rotavirus disease.Acknowledgments
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